Measuring Redox Status of Melanoma Cells

Autor: Liu-Smith, F, Krasieva, TB, Liu, J, Meyskens, FL

Publikováno v: Liu-Smith, F; Krasieva, TB; Liu, J; Liu, J; & Meyskens, FL. (2016). Measuring Redox Status of Melanoma Cells.. Methods in molecular biology (Clifton, N.J.). doi: 10.1007/7651_2016_352. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/0492z7h2

Redox homeostasis plays multiple roles in essentially all aspects of cellular function, and hence, reliable methods for measuring cellular or tissue redox status are key elements in understanding the redox related signal pathways. However, in the fre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::6f8ce4ae233c0526cf6de93d0112049c
http://www.escholarship.org/uc/item/0492z7h2

Unique metabolic profile of Vemurafenib-resistant melanoma cells: a quantitative proteomics approach

Autor: Syed, DN, Lall, RK, Majeed, R, Liu, F, Meyskens, FL, Mukhtar, H

Publikováno v: Syed, DN; Lall, RK; Majeed, R; Liu, F; Meyskens, FL; & Mukhtar, H. (2015). Unique metabolic profile of Vemurafenib-resistant melanoma cells: a quantitative proteomics approach. CANCER RESEARCH, 75. doi: 10.1158/1538-7445.AM2015-1179. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/5vd376n7

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::d8a67769e67e46e2b9c6aa1c3f639753
http://www.escholarship.org/uc/item/5vd376n7

A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum

Autor: Gillen, DL, Meyskens, FL, Morgan, TR, Zell, JA, Carroll, R, Benya, R, Chen, WP, Mo, A, Tucker, C, Bhattacharya, A, Huang, Z, Arcilla, M, Wong, V, Chung, J, Gonzalez, R, Rodriguez, LM, Szabo, E, Rosenberg, DW, Lipkin, SM

Publikováno v: Gillen, DL; Meyskens, FL; Morgan, TR; Zell, JA; Carroll, R; Benya, R; et al.(2015). A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum. Cancer Prevention Research, 8(3), 222-230. doi: 10.1158/1940-6207.CAPR-14-0148. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/7sm974c3

© 2015 American Association for Cancer Research. Colorectal cancer progresses through multiple distinct stages that are potentially amenable to chemopreventative intervention. Epidermal growth factor receptor (EGFR) inhibitors are efficacious in adv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::40648a9acbdfa9ed78185d6216f67089
http://www.escholarship.org/uc/item/7sm974c3

Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance)

Autor: Unger, JM, Phillips, K-A, Boyle, FM, Hitre, E, Porter, DJ, Francis, PA, Minasian, LM, Gelber, RD, Goldstein, LJ, Gomez, HL, Vallejos, C, Partridge, AH, Dakhil, SR, Martino, S, Barlow, WE, Fabian, CJ, Meyskens, FL, Hortobagyi, GN, Albain, KS

Publikováno v: Unger, JM; Phillips, K-A; Boyle, FM; Hitre, E; Porter, DJ; Francis, PA; et al.(2014). Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(18_suppl), LBA505. doi: 10.1200/jco.2014.32.18_suppl.lba505. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/3rg743fk

LBA505 Background: Premature ovarian failure (POF) is a common toxicity of CT. Risk depends on type and amount of CT, age, and perhaps ovarian cycling at the time of CT. POEMS is a SWOG-coordinated phase III randomized study to evaluate whether LHRH

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::371872d38470b88fa0b752c584339a02
http://www.escholarship.org/uc/item/3rg743fk

Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine

Autor: Meyskens, FL, Simoneau, AR, Gerner, EW

Publikováno v: Meyskens, FL; Simoneau, AR; & Gerner, EW. (2014). Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine.. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 202, 115-120. doi: 10.1007/978-3-642-45195-9_14. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/3kv0t9c4

In vitro and in vivo preclinical results suggest that inhibition of polyamine synthesis inhibits the progression of prostate cancer. These findings has led to two clinical trials in patients at risk for invasive prostate cancer with difluoromethylorn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::db89c453bedc839b0ecc91ac024dc4f1
http://www.escholarship.org/uc/item/3kv0t9c4